Ferroptosis-centered Drug Response Information

General Information of the Drug (ID: ferrodrug0085)
Name
Carvedilol
Synonyms
carvedilol; 72956-09-3; Coreg; Dilatrend; Eucardic; Kredex; Carvedilolum [Latin]; Carvedilolum; Querto; BM 14190; 1-(9H-Carbazol-4-yloxy)-3-[[2-(2-methoxyphenoxy)ethyl]amino]-2-propanol; BM-14190; Dimitone; Artist; SKF 105517; 1-((9H-Carbazol-4-yl)oxy)-3-((2-(2-methoxyphenoxy)ethyl)amino)propan-2-ol; Coronis; Korvasan; Talliton; DQ 2466; 1-(9H-carbazol-4-yloxy)-3-[2-(2-methoxyphenoxy)ethylamino]propan-2-ol; DQ-2466; (+-)-1-(Carbazol-4-yloxy)-3-((2-(o-methoxyphenoxy)ethyl)amino)-2-propanol; (+/-)-Carvedilol-d4; CHEMBL723; NSC-758694; SK&F-105517; [3-(9H-carbazol-4-yloxy)-2-hydroxypropyl][2-(2-methoxyphenoxy)ethyl]amine; BM 14.190; BM-14-190; BM-14.190; CHEBI:3441; C07AG02; 0K47UL67F2; SKF-105517; Carvedilol-methyl-d3; 1-(9H-carbazol-4-yloxy)-3-{[2-(2-methoxyphenoxy)ethyl]amino}propan-2-ol; Coropress; Dibloc; 1-(9H-carbazol-4-yloxy)-3-[(2-{[2-(methyloxy)phenyl]oxy}ethyl)amino]propan-2-ol; SMR000449280; Artist (TN); Coreg (TN); HSDB 7044; SR-01000759289; UNII-0K47UL67F2; MFCD00869663; 1-(9H-Carbazol-4-yloxy)-3-(2-(2-methoxyphenoxy)ethylamino)propan-2-ol; EG-P042; (R)-BM 14190; MFCD00864692; Carvedilol - Bio-X; BM14190; Carvedilol [USAN:USP:INN:BAN:JAN]; Spectrum_001665; CARVEDILOL [MI]; CARVEDILOL [INN]; CARVEDILOL [JAN]; Spectrum2_001673; Spectrum3_001182; Spectrum4_000636; Spectrum5_001436; CARVEDILOL [HSDB]; CARVEDILOL [USAN]; CARVEDILOL [VANDF]; CARVEDILOL [MART.]; CARVEDILOL [USP-RS]; CARVEDILOL [WHO-DD]; SCHEMBL22293; GTPL551; KBioGR_001252; KBioSS_002145; MLS000758299; MLS000759508; MLS001424092; MLS006011886; SPBio_001885; Carvedilol (JP17/USP/INN); CARVEDILOL [ORANGE BOOK]; DTXSID8022747; SCHEMBL10082334; SCHEMBL13287211; BDBM25759; KBio2_002145; KBio2_004713; KBio2_007281; KBio3_002323; CARVEDILOL [EP MONOGRAPH]; (R)-1-[(4-Carbazolyl)oxy]-3-[[2-(2-methoxyphenoxy)ethyl]amino]-2-propanol; OGHNVEJMJSYVRP-UHFFFAOYSA-N; CARVEDILOL [USP MONOGRAPH]; HMS2051N03; HMS2089B09; HMS2093E12; HMS3261E15; HMS3269N11; HMS3393N03; HMS3413B14; HMS3655O14; HMS3677B14; HMS3715D15; HMS3750I15; HMS3884E12; Pharmakon1600-01504257; Carvedilol 1.0 mg/ml in Methanol; AMY40801; BCP23386; EX-A5746; HY-B0006; Tox21_500347; BBL029064; MFCD00869664; NSC758694; s1831; STK621453; AKOS005554967; Carvedilol, >=98% (HPLC), solid; AC-1641; BCP9000493; CCG-100917; CCG-207952; CS-1194; DB01136; KS-1037; LP00347; NC00167; NSC 758694; SB17441; SDCCGSBI-0206771.P002; 2-Propanol, 1-(9H-carbazol-4-yloxy)-3-((2-(2-methoxyphenoxy)ethyl)amino)-, (+-)-; NCGC00167832-01; NCGC00167832-02; NCGC00167832-03; NCGC00167832-04; NCGC00167832-19; NCGC00261032-01; BC164291; SY129821; SY283162; BCP0726000253; SBI-0206771.P001; C2260; FT-0603055; FT-0603057; FT-0652640; FT-0664397; SW197547-3; C06875; D00255; F19969; AB00639903-07; AB00639903-09; AB00639903_10; AB00639903_11; AB00639903_12; L001243; Q412534; Q-200801; SR-01000759289-5; SR-01000759289-6; SR-01000759289-9; BRD-A10977446-001-04-8; BRD-A10977446-001-05-5; BRD-A10977446-045-01-1; Z1515383337; Carvedilol, European Pharmacopoeia (EP) Reference Standard; Ethyl 2-(9-(pyridin-4-ylmethyl)-9H-fluoren-9-yl)acetate; Carvedilol, United States Pharmacopeia (USP) Reference Standard; 1-(9H-carbazol-4-yloxy)-3-[2-(2-methoxy-phenoxy)-ethylamino]-propan-2-ol; Carvedilol, Pharmaceutical Secondary Standard; Certified Reference Material; (+/-)-1-CARBAZOL-4-YLOXY)-3-((2-(O-METHOXYPHENOXY)ETHYL)AMINO)-2-PROPANOL; 1-(CARBAZOL-4-YLOXY)-3-((2-(O-METHOXY-PHENOXY)ETHYL)AMINO)-2-PROPANOL; Carvedilol for system suitability, European Pharmacopoeia (EP) Reference Standard; 107741-96-8; 2-PROPANOL, 1-(9H-CARBAZOL-4-YLOXY)-3-((2-(2-METHOXYPHENOXY)ETHYL)AMINO)-, (+/-)-

    Click to Show/Hide
Structure
Formula
C24H26N2O4
IUPAC Name
1-(9H-carbazol-4-yloxy)-3-[2-(2-methoxyphenoxy)ethylamino]propan-2-ol
Canonical SMILES
COC1=CC=CC=C1OCCNCC(COC2=CC=CC3=C2C4=CC=CC=C4N3)O
InChI
InChI=1S/C24H26N2O4/c1-28-21-10-4-5-11-22(21)29-14-13-25-15-17(27)16-30-23-12-6-9-20-24(23)18-7-2-3-8-19(18)26-20/h2-12,17,25-27H,13-16H2,1H3
InChIKey
OGHNVEJMJSYVRP-UHFFFAOYSA-N
PubChem CID
2585
Full List of Ferroptosis Target Related to This Drug
Unspecific Target
In total 1 item(s) under this Target
Experiment 1 Reporting the Ferroptosis-centered Drug Act on This Target [1]
Responsed Disease Acute kidney failure ICD-11: GB60
 Disease Info 
Pathway Response Fatty acid metabolism hsa01212
Ferroptosis hsa04216
Cell Process Cell ferroptosis
In Vitro Model CHO-S/H9C2 cells Normal Cricetulus griseus CVCL_A0TS
NRK-49F cells Normal Rattus norvegicus CVCL_2144
HK-2 cells Normal Homo sapiens CVCL_0302
C2C12 cells Normal Mus musculus CVCL_0188
MDA-MB-231 cells Breast adenocarcinoma Homo sapiens CVCL_0062
NRK-52E cells Normal Rattus norvegicus CVCL_0468
LLC-PK1 cells Normal Sus scrofa CVCL_0391
PANC-1 cells Pancreatic ductal adenocarcinoma Homo sapiens CVCL_0480
HT22 cells Normal Mus musculus CVCL_0321
hUPECs (Human urine-derived podocyte-like epithelial cells)
In Vivo Model
C57BL/6N male mice (CLEA Japan), aged 8-9 weeks, were used. AKI was induced by intraperitoneal injection of cisplatin solution (16 or 17 mg/kg as indicated; Nichi-Iko Pharmaceutical). Mice were orally treated with water only, promethazine (20 mg/kg in water), or rifampicin (20 mg/kg in 0.5% methylcellulose) every 12 hours for 4 days starting 30 minutes before the cisplatin injection, or orally treated with promethazine (20 mg/kg) in the following groups: (1) no promethazine, (2) pretreatment 30 minutes before cisplatin injection, (3) treatment from 30 minutes before injection to 24 hours after injection, (4) treatment from 24 to 96 hours after injection, and (5) treatment every 12 hours from 30 minutes before injection to 96 hours after injection.

    Click to Show/Hide
Response regulation Eight drugs and hormones that showed antiferroptotic activity, including omeprazole, indole-3-carbinol, rifampicin, promethazine, carvedilol, propranolol, estradiol, and triiodothyronine. Moreover, in mice, the drugs ameliorated acute kidney injury and liver injury, with suppression of tissue lipid peroxidation and decreased cell death.
References
Ref 1 Drugs Repurposed as Antiferroptosis Agents Suppress Organ Damage, Including AKI, by Functioning as Lipid Peroxyl Radical Scavengers. J Am Soc Nephrol. 2020 Feb;31(2):280-296. doi: 10.1681/ASN.2019060570. Epub 2019 Nov 25.